{'fraction_non_alphanumeric': 0.036702127659574466, 'fraction_numerical': 0.02553191489361702, 'mean_word_length': 5.147058823529412, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical case on the use of oral vinorelbine in the treatment of disseminated estrogen receptor-positive HER2-negative breast cancer

Luminal B (HER2-negative) breast cancer is considered the most common type. The consistent prescription of hormone therapy lines for disseminated estrogen receptor-positive (ER+) HER2-negative breast cancer allows us to consider this variant of the tumor as a chronic disease with long-term oral therapy. Oral chemotherapy can improve the life quality of patients while ensuring the high efficiency of the treatment. If there is a standard for the first lines of hormone therapy, the optimal chemotherapy regimen of line 1 is not established and is determined individually in each case. The authors note that it is necessary to rely on the expected toxicity of therapy and the toxicity of previous treatment, as well as take into account the patient’s willingness to visit the clinic for intravenous infusions. The article presents a clinical case concerning a patient suffering from disseminated ER+ HER2-negative breast cancer. This clinical case shows how it is possible to postpone the prescription of intravenous chemotherapy as much as possible (with the rational use of hormone therapy regimens, as well as oral chemotherapy), thereby improving the patient’s life quality. In the context of the COVID-19 pandemic, which involves limiting visits to medical institutions, oral chemotherapy can be considered as the therapy of choice for such patients. KEYWORDS: chemotherapy, breast cancer, toxicity, vinorelbin, estrogen receptor-positive cancer, HER2-negative cancer. FOR CITATION: Glazkova E.V., Stenina M.B. Clinical case on the use of oral vinorelbine in the treatment of disseminated estrogen receptorpositive HER2-negative breast cancer. Russian Medical Inquiry. 2021;5(8):548–551 (in Russ.). DOI: 10.32364/2587-6821-2021-5-8-548-551.